Home › Funds › ACUTA CAPITAL PARTNERS, LLC › AVTX
ACUTA CAPITAL PARTNERS, LLC position in AVTX
AVALO THERAPEUTICS INC · Health Care
ACUTA CAPITAL PARTNERS, LLC reported holding 186,308 shares of AVTX (AVALO THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$3.4M, representing 2.40% of its reported portfolio and ranking #17 among its reported holdings. ACUTA CAPITAL PARTNERS, LLC has disclosed AVTX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ACUTA CAPITAL PARTNERS, LLC's AVTX position evolved
ACUTA CAPITAL PARTNERS, LLC first disclosed a stake in AVTX in Q1 2026 at 60,808 shares (US$908K). The position peaked in Q2 2026 at 186,308 shares, worth US$3.4M. Across 2 filings, ACUTA CAPITAL PARTNERS, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 186,308 shares valued at US$3.4M — an increase of 125,500 shares quarter over quarter.. Notable position changes include a 206% increase in Q2 2026 (shares fell 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 60.81K | $907.86K | New |
| Q2 2026 | 186.31K | $3.44M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVTX and 13F data
AVTX (AVALO THERAPEUTICS INC) is a Health Care company. 83 other funds we track also report a position in AVTX — the largest reported positions include Deep Track Capital, LP (US$66.7M), Caligan Partners LP (US$58.5M), TCG Crossover Management, LLC (US$55.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVTX
- Deep Track Capital, LP 3.61M sh · $66.71M · Q2 2026
- Caligan Partners LP 3.16M sh · $58.47M · Q2 2026
- TCG Crossover Management, LLC 3.02M sh · $55.76M · Q2 2026
- Affinity Asset Advisors, LLC 2.90M sh · $53.59M · Q2 2026
- Farallon Capital Management 2.50M sh · $46.16M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 2.50M sh · $46.16M · Q2 2026
- Avoro Capital Advisors LLC 2.33M sh · $43.12M · Q2 2026
- BVF INC/IL 2.08M sh · $38.36M · Q2 2026
- Nantahala Capital Management, LLC 1.86M sh · $34.41M · Q2 2026
- Soleus Capital Management, L.P. 1.65M sh · $30.58M · Q2 2026
- BRAIDWELL LP 1.63M sh · $30.11M · Q2 2026
- Logos Global Management LP 1.15M sh · $21.25M · Q2 2026
More on ACUTA CAPITAL PARTNERS, LLC
FAQ
How long has ACUTA CAPITAL PARTNERS, LLC held AVTX?
ACUTA CAPITAL PARTNERS, LLC has disclosed AVTX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is ACUTA CAPITAL PARTNERS, LLC's current position in AVTX?
As of Q2 2026, ACUTA CAPITAL PARTNERS, LLC holds 186.31K shares of AVTX (AVALO THERAPEUTICS INC), valued at $3.44M, representing 2.40% of its reported portfolio and ranking #17.
Has ACUTA CAPITAL PARTNERS, LLC been buying or selling AVTX?
In the latest 13F filing (Q2 2026), ACUTA CAPITAL PARTNERS, LLC increased its position in AVTX. The position peaked in Q2 2026 at 186.31K shares.
Which other funds hold AVTX?
Other major institutional holders of AVTX include Deep Track Capital, LP, Caligan Partners LP, TCG Crossover Management, LLC, among 83 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.